Ignite Creation Date:
2024-05-06 @ 1:53 AM
Last Modification Date:
2024-10-26 @ 11:11 AM
Study NCT ID:
NCT01925352
Status:
UNKNOWN
Last Update Posted:
2013-08-20
First Post:
2013-08-15
Brief Title:
Safety Study of Adenovirus Hepatocyte Growth Factor to Treat Ischemic Heart Disease
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
Phase 2 Study of Adenovirus Hepatocyte Growth Factor for Treatment of Ischemic Heart Disease
Status:
UNKNOWN
Status Verified Date:
2013-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To explore the safety and efficiency of adenovirus-hepatocyte growth factorAd-HGF treatment in ischemic heart disease
Detailed Description:
1 Ischemic heart disease refers to a group of closely related syndromes by an imbalance between the myocardial oxygen demand and the blood supply
2 Gene therapy offers an attractive alternative to current pharmacologic therapies and may be beneficial in refractory disease Gene therapy with hepatocyte growth factor induces angiogenesis decreases apoptosis and leads to protection in the ischemic heart In this study we mainly explore the safety and effects of adenovirus hepatocyte growth factor for the treatment of ischemic heart disease
2 Gene therapy offers an attractive alternative to current pharmacologic therapies and may be beneficial in refractory disease Gene therapy with hepatocyte growth factor induces angiogenesis decreases apoptosis and leads to protection in the ischemic heart In this study we mainly explore the safety and effects of adenovirus hepatocyte growth factor for the treatment of ischemic heart disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None